Stony Brook University: Research to Revenue

Stony Brook University

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 69 commercialization opportunities from Stony Brook University and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of Stony Brook University's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

72/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

6/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

72/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1957

First Nobel

1965

First Patent

1960

First IPO

N/A

2022-2024

AI-driven diagnostics

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1985

Patent Milestone

First patent licensed

1985

Startup Formation

Spin-off companies created

1990s

Research Breakthrough

Biotech innovation patented

2000

Tech Transfer

Record licensing revenue

2010

Industry Partnership

Collaboration with pharma

2015

Competitive Benchmarking

Stony Brook University vs. Peer Research Universities

Stony Brook University vs Peers Comparison

Metric	Stony Brook University (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$325M	$855M	$1,675M
New Inventions Disclosed	1	200	400
Startups Formed	2	7	10
Visibility Index	13	12	23
Licensing Revenue	$2M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. AI-Driven Drug Discovery Accelerates Therapeutics Development

Stony Brook's AI platform reduces drug discovery timelines, addressing critical pharmaceutical R&D inefficiencies, enabling scalable, cost-effective development of novel therapies with competitive precision.

2. Sustainable Battery Technology Enhances Energy Storage Efficiency

Innovative battery materials improve storage capacity and longevity, meeting growing renewable energy demands with scalable, eco-friendly solutions, positioning Stony Brook at the forefront of clean energy tech.

3. Advanced Cancer Immunotherapy Platforms Boost Treatment Outcomes

Breakthrough immunotherapy techniques enhance patient response rates, tackling cancer's complexity with scalable, personalized medicine approaches, offering competitive advantage in the expanding oncology market.

4. Quantum Computing Algorithms Optimize Complex Data Processing

Stony Brook develops scalable quantum algorithms that solve previously intractable problems, providing competitive edge in industries like finance, logistics, and cryptography with transformative market potential.

5. Smart Sensor Networks Revolutionize Environmental Monitoring

Robust, scalable sensor systems enable real-time, precise environmental data collection, addressing climate change challenges and regulatory needs, creating market-leading solutions with broad applicability.

6. Innovative Neuroscience Tools Enable Next-Gen Brain Research

Cutting-edge neural interface technologies facilitate scalable, high-resolution brain mapping, advancing treatments for neurological disorders and positioning Stony Brook as a leader in neurotech commercialization.